ESSA Pharma Inc. (NASDAQ:EPIX) Short Interest Update

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 802,800 shares, a drop of 13.5% from the March 15th total of 928,600 shares. Based on an average trading volume of 154,100 shares, the days-to-cover ratio is presently 5.2 days.

ESSA Pharma Stock Up 1.8 %

ESSA Pharma stock traded up $0.13 during mid-day trading on Tuesday, reaching $7.43. 17,099 shares of the company’s stock were exchanged, compared to its average volume of 141,466. The business’s fifty day simple moving average is $8.82 and its 200 day simple moving average is $6.94. The firm has a market capitalization of $328.70 million, a PE ratio of -12.59 and a beta of 1.62. ESSA Pharma has a one year low of $2.56 and a one year high of $11.67.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its earnings results on Tuesday, February 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, sell-side analysts forecast that ESSA Pharma will post -0.8 earnings per share for the current year.

Institutional Trading of ESSA Pharma

Large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SNC increased its position in ESSA Pharma by 528.6% in the first quarter. BNP Paribas Arbitrage SNC now owns 9,429 shares of the company’s stock worth $28,000 after buying an additional 7,929 shares during the last quarter. Bank of America Corp DE increased its position in ESSA Pharma by 41.7% in the first quarter. Bank of America Corp DE now owns 11,614 shares of the company’s stock worth $72,000 after buying an additional 3,420 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in ESSA Pharma in the first quarter worth $47,000. Jane Street Group LLC purchased a new stake in ESSA Pharma in the first quarter worth $154,000. Finally, Renaissance Technologies LLC purchased a new stake in ESSA Pharma in the second quarter worth $81,000. 75.12% of the stock is owned by hedge funds and other institutional investors.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.